Nyt fra tidsskrifterne
Klik på knappen for at kopiere eller tryk på linket nedenfor.
Kopieret til udklipsholder!
https://www.infmed.dk/nyheder-udefra?rss_filter=omicron&setpoint=70479#101256
Klik på knappen for at kopiere eller tryk på linket nedenfor.
Kopieret til udklipsholder!
https://www.infmed.dk/nyheder-udefra?rss_filter=omicron&setpoint=70479#101250
Klik på knappen for at kopiere eller tryk på linket nedenfor.
Kopieret til udklipsholder!
https://www.infmed.dk/nyheder-udefra?rss_filter=omicron&setpoint=70479#101191
Klik på knappen for at kopiere eller tryk på linket nedenfor.
Kopieret til udklipsholder!
https://www.infmed.dk/nyheder-udefra?rss_filter=omicron&setpoint=70479#101148
Klik på knappen for at kopiere eller tryk på linket nedenfor.
Kopieret til udklipsholder!
https://www.infmed.dk/nyheder-udefra?rss_filter=omicron&setpoint=70479#101091
Klik på knappen for at kopiere eller tryk på linket nedenfor.
Kopieret til udklipsholder!
https://www.infmed.dk/nyheder-udefra?rss_filter=omicron&setpoint=70479#101078
Klik på knappen for at kopiere eller tryk på linket nedenfor.
Kopieret til udklipsholder!
https://www.infmed.dk/nyheder-udefra?rss_filter=omicron&setpoint=70479#100970
Klik på knappen for at kopiere eller tryk på linket nedenfor.
Kopieret til udklipsholder!
https://www.infmed.dk/nyheder-udefra?rss_filter=omicron&setpoint=70479#100963
Klik på knappen for at kopiere eller tryk på linket nedenfor.
Kopieret til udklipsholder!
https://www.infmed.dk/nyheder-udefra?rss_filter=omicron&setpoint=70479#100940
Klik på knappen for at kopiere eller tryk på linket nedenfor.
Kopieret til udklipsholder!
https://www.infmed.dk/nyheder-udefra?rss_filter=omicron&setpoint=70479#100927
Klik på knappen for at kopiere eller tryk på linket nedenfor.
Kopieret til udklipsholder!
https://www.infmed.dk/nyheder-udefra?rss_filter=omicron&setpoint=70479#100916
Klik på knappen for at kopiere eller tryk på linket nedenfor.
Kopieret til udklipsholder!
https://www.infmed.dk/nyheder-udefra?rss_filter=omicron&setpoint=70479#100918
Klik på knappen for at kopiere eller tryk på linket nedenfor.
Kopieret til udklipsholder!
https://www.infmed.dk/nyheder-udefra?rss_filter=omicron&setpoint=70479#100793
Klik på knappen for at kopiere eller tryk på linket nedenfor.
Kopieret til udklipsholder!
https://www.infmed.dk/nyheder-udefra?rss_filter=omicron&setpoint=70479#100546
Klik på knappen for at kopiere eller tryk på linket nedenfor.
Kopieret til udklipsholder!
https://www.infmed.dk/nyheder-udefra?rss_filter=omicron&setpoint=70479#100449
Klik på knappen for at kopiere eller tryk på linket nedenfor.
Kopieret til udklipsholder!
https://www.infmed.dk/nyheder-udefra?rss_filter=omicron&setpoint=70479#100437
Klik på knappen for at kopiere eller tryk på linket nedenfor.
Kopieret til udklipsholder!
https://www.infmed.dk/nyheder-udefra?rss_filter=omicron&setpoint=70479#100433
Klik på knappen for at kopiere eller tryk på linket nedenfor.
Kopieret til udklipsholder!
https://www.infmed.dk/nyheder-udefra?rss_filter=omicron&setpoint=70479#100425
Klik på knappen for at kopiere eller tryk på linket nedenfor.
Kopieret til udklipsholder!
https://www.infmed.dk/nyheder-udefra?rss_filter=omicron&setpoint=70479#100377
Klik på knappen for at kopiere eller tryk på linket nedenfor.
Kopieret til udklipsholder!
https://www.infmed.dk/nyheder-udefra?rss_filter=omicron&setpoint=70479#100360
Klik på knappen for at kopiere eller tryk på linket nedenfor.
Kopieret til udklipsholder!
https://www.infmed.dk/nyheder-udefra?rss_filter=omicron&setpoint=70479#100309
Klik på knappen for at kopiere eller tryk på linket nedenfor.
Kopieret til udklipsholder!
https://www.infmed.dk/nyheder-udefra?rss_filter=omicron&setpoint=70479#100234
Klik på knappen for at kopiere eller tryk på linket nedenfor.
Kopieret til udklipsholder!
https://www.infmed.dk/nyheder-udefra?rss_filter=omicron&setpoint=70479#100179
Klik på knappen for at kopiere eller tryk på linket nedenfor.
Kopieret til udklipsholder!
https://www.infmed.dk/nyheder-udefra?rss_filter=omicron&setpoint=70479#100121
Klik på knappen for at kopiere eller tryk på linket nedenfor.
Kopieret til udklipsholder!
https://www.infmed.dk/nyheder-udefra?rss_filter=omicron&setpoint=70479#99962
Klik på knappen for at kopiere eller tryk på linket nedenfor.
Kopieret til udklipsholder!
https://www.infmed.dk/nyheder-udefra?rss_filter=omicron&setpoint=70479#99878
Klik på knappen for at kopiere eller tryk på linket nedenfor.
Kopieret til udklipsholder!
https://www.infmed.dk/nyheder-udefra?rss_filter=omicron&setpoint=70479#99841
Klik på knappen for at kopiere eller tryk på linket nedenfor.
Kopieret til udklipsholder!
https://www.infmed.dk/nyheder-udefra?rss_filter=omicron&setpoint=70479#99800
Klik på knappen for at kopiere eller tryk på linket nedenfor.
Kopieret til udklipsholder!
https://www.infmed.dk/nyheder-udefra?rss_filter=omicron&setpoint=70479#99767
Klik på knappen for at kopiere eller tryk på linket nedenfor.
Kopieret til udklipsholder!
https://www.infmed.dk/nyheder-udefra?rss_filter=omicron&setpoint=70479#99743
Klik på knappen for at kopiere eller tryk på linket nedenfor.
Kopieret til udklipsholder!
https://www.infmed.dk/nyheder-udefra?rss_filter=omicron&setpoint=70479#99705
Klik på knappen for at kopiere eller tryk på linket nedenfor.
Kopieret til udklipsholder!
https://www.infmed.dk/nyheder-udefra?rss_filter=omicron&setpoint=70479#99681
Klik på knappen for at kopiere eller tryk på linket nedenfor.
Kopieret til udklipsholder!
https://www.infmed.dk/nyheder-udefra?rss_filter=omicron&setpoint=70479#99648
Klik på knappen for at kopiere eller tryk på linket nedenfor.
Kopieret til udklipsholder!
https://www.infmed.dk/nyheder-udefra?rss_filter=omicron&setpoint=70479#99614
Klik på knappen for at kopiere eller tryk på linket nedenfor.
Kopieret til udklipsholder!
https://www.infmed.dk/nyheder-udefra?rss_filter=omicron&setpoint=70479#99622
Klik på knappen for at kopiere eller tryk på linket nedenfor.
Kopieret til udklipsholder!
https://www.infmed.dk/nyheder-udefra?rss_filter=omicron&setpoint=70479#99535
Klik på knappen for at kopiere eller tryk på linket nedenfor.
Kopieret til udklipsholder!
https://www.infmed.dk/nyheder-udefra?rss_filter=omicron&setpoint=70479#99515
Klik på knappen for at kopiere eller tryk på linket nedenfor.
Kopieret til udklipsholder!
https://www.infmed.dk/nyheder-udefra?rss_filter=omicron&setpoint=70479#99411
Klik på knappen for at kopiere eller tryk på linket nedenfor.
Kopieret til udklipsholder!
https://www.infmed.dk/nyheder-udefra?rss_filter=omicron&setpoint=70479#99402
Klik på knappen for at kopiere eller tryk på linket nedenfor.
Kopieret til udklipsholder!
https://www.infmed.dk/nyheder-udefra?rss_filter=omicron&setpoint=70479#99386
Klik på knappen for at kopiere eller tryk på linket nedenfor.
Kopieret til udklipsholder!
https://www.infmed.dk/nyheder-udefra?rss_filter=omicron&setpoint=70479#99384
Klik på knappen for at kopiere eller tryk på linket nedenfor.
Kopieret til udklipsholder!
https://www.infmed.dk/nyheder-udefra?rss_filter=omicron&setpoint=70479#99382
Klik på knappen for at kopiere eller tryk på linket nedenfor.
Kopieret til udklipsholder!
https://www.infmed.dk/nyheder-udefra?rss_filter=omicron&setpoint=70479#99300
Klik på knappen for at kopiere eller tryk på linket nedenfor.
Kopieret til udklipsholder!
https://www.infmed.dk/nyheder-udefra?rss_filter=omicron&setpoint=70479#99281
Klik på knappen for at kopiere eller tryk på linket nedenfor.
Kopieret til udklipsholder!
https://www.infmed.dk/nyheder-udefra?rss_filter=omicron&setpoint=70479#99240
Klik på knappen for at kopiere eller tryk på linket nedenfor.
Kopieret til udklipsholder!
https://www.infmed.dk/nyheder-udefra?rss_filter=omicron&setpoint=70479#99110
Klik på knappen for at kopiere eller tryk på linket nedenfor.
Kopieret til udklipsholder!
https://www.infmed.dk/nyheder-udefra?rss_filter=omicron&setpoint=70479#99053
Klik på knappen for at kopiere eller tryk på linket nedenfor.
Kopieret til udklipsholder!
https://www.infmed.dk/nyheder-udefra?rss_filter=omicron&setpoint=70479#98996
Klik på knappen for at kopiere eller tryk på linket nedenfor.
Kopieret til udklipsholder!
https://www.infmed.dk/nyheder-udefra?rss_filter=omicron&setpoint=70479#98806
Klik på knappen for at kopiere eller tryk på linket nedenfor.
Kopieret til udklipsholder!
https://www.infmed.dk/nyheder-udefra?rss_filter=omicron&setpoint=70479#98777
Søgeord (omicron) valgt.
781 emner vises.
Journal of Infectious Diseases, 28.03.2024
Tilføjet 28.03.2024
Abstract Background SARS-CoV-2 antigen-detection rapid diagnostic tests (Ag-RDTs) have become widely utilized but longitudinal characterization of their community-based performance remains incompletely understood.Methods This prospective longitudinal study at a large public university in Seattle, WA utilized remote enrollment, online surveys, and self-collected nasal swab specimens to evaluate Ag-RDT performance against real-time reverse transcription polymerase chain reaction (rRT-PCR) in the context of SARS-CoV-2 Omicron. Ag-RDT sensitivity and specificity within 1 day of rRT-PCR were evaluated by symptom status throughout the illness episode and Orf1b cycle threshold (Ct).Results From February to December 2022, 5,757 participants reported 17,572 Ag-RDT results and completed 12,674 rRT-PCR tests, of which 995 (7.9%) were rRT-PCR-positive. Overall sensitivity and specificity were 53.0% (95% CI: 49.6–56.4%) and 98.8% (98.5–99.0%), respectively. Sensitivity was comparatively higher for Ag-RDTs used 1 day after rRT-PCR (69.0%), 4 to 7 days post-symptom onset (70.1%), and Orf1b Ct ≤20 (82.7%). Serial Ag-RDT sensitivity increased with repeat testing ≥2 (68.5%) and ≥4 (75.8%) days after an initial Ag-RDT-negative result.Conclusion Ag-RDT performance varied by clinical characteristics and temporal testing patterns. Our findings support recommendations for serial testing following an initial Ag-RDT-negative result, especially among recently symptomatic persons or those at high-risk for SARS-CoV-2 infection.
Læs mere Tjek på PubMedBMC Infectious Diseases, 28.03.2024
Tilføjet 28.03.2024
Abstract Background The prevalence and distinction between first Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection and reinfection with the Omicron variant among healthcare workers (HCWs) remain unclear. Methods A cross-sectional study was conducted at a hospital in Southern China. The study included 262 HCWs who were infected with SARS-CoV-2 between April and June 2023, with 101 cases of first infection and 161 ones of reinfection. Student’s t-test, Analysis of Variance (ANOVA), and Mann-Whitney U tests were used based on the distribution of quantitative variables. Pearson’s chi-square and Fisher’s exact tests were used based on the expected frequencies of categorical variables. Results The reinfection rate among HCWs was 11.5% (161/1406). The majority of the infected HCWs were female (212/262, 80.9%, first infection vs. reinfection: 76.2% vs. 83.9%). The nursing staff, had the highest percentage of SARS-CoV-2 infection (42.0%), especially of its reinfection (47.8%). Out of the 262 infected individuals, 257 had received SARS-CoV-2 vaccination, primarily inactivated vaccines (243/257, 91.1%). The first infection group, which received four doses (24, 23.8%), was significantly higher than that in the reinfection group (6, 3.7%) (P
Læs mere Tjek på PubMedClinical Infectious Diseases, 26.03.2024
Tilføjet 26.03.2024
Abstract Background Asymptomatic SARS-CoV-2 infection in children is highly prevalent but its acute and chronic implications have been minimally described.Methods In this controlled case-ascertained household transmission study, we recruited asymptomatic children
Læs mere Tjek på PubMedPaula Martínez de Aguirre, Silvia Carlos, Manuel Pina‐Sánchez, Samclide Mbikayi, Eduardo Burgueño, Céline Tendobi, Luis Chiva, África Holguín, Gabriel Reina
Journal of Medical Virology, 23.03.2024
Tilføjet 23.03.2024
Guanhua Zha, Zhiwei Chen, Na Wu, Tianquan Huang, Zhiling Deng, Dachuan Cai, Mingli Peng, Peng Hu, Hong Ren
Journal of Medical Virology, 22.03.2024
Tilføjet 22.03.2024
BMC Infectious Diseases, 22.03.2024
Tilføjet 22.03.2024
Abstract Background There is a significant increase in the number of SARS-CoV-2 reinfection reports in various countries. However, the trend of reinfection rate over time is not clear. Methods We searched PubMed, Web of Science, Medline, Embase, Cochrane Central Register of Controlled Trials, China National Knowledge Infrastructure, and Wanfang for cohort studies, case-control studies, and cross-sectional studies up to March 16, 2023, to conduct a meta-analysis of global SARS-CoV-2 reinfection rate. Subgroup analyses were performed for age, country, study type, and study population, and time-varying reinfection rates of SARS-CoV-2 were estimated using meta-regression. The risk of bias was assessed using the Newcastle-Ottawa Scale and the Joanna Briggs Institute critical appraisal tool. Result A total of 55 studies involving 111,846 cases of SARS-CoV-2 reinfection were included. The pooled SARS-CoV-2 reinfection rate was 0.94% (95% CI: 0.65 -1.35%). In the subgroup analyses, there were statistically significant differences in the pooled reinfection rates by reinfection variant, and study type (P
Læs mere Tjek på PubMedLiuhai Zheng, Huifang Wang, Xueyan Liu, Chengchao Xu, Mingxiong Tian, Guangwei Shi, Chongzhi Bai, Zhijie Li, Jigang Wang, Shuwen Liu
Journal of Medical Virology, 20.03.2024
Tilføjet 20.03.2024
Avika Dixit, Richard Bennett, Kashif Ali, Carl Griffin, Robert A Clifford, Mark Turner, Rosanne Poston, Kelly Hautzinger, Anne Yeakey, Bethany Girard, Wen Zhou, Weiping Deng, Honghong Zhou, Sabine Schnyder Ghamloush, Barbara J Kuter, Karen Slobod, Jacqueline M Miller, Frances Priddy, Rituparna Das, ROVER Study Investigators
Lancet Infectious Diseases, 20.03.2024
Tilføjet 20.03.2024
mRNA-1273.214 was immunogenic against BA.1 and D614G in children aged 6 months to 5 years, with a comparable safety profile to mRNA-1273, when given as a two-dose primary series or a booster dose. These results are aligned with the US Centers for Disease Control and Prevention recommendations for the use of variant-containing vaccines for continued protection against the emerging variants of SARS-CoV-2.
Læs mere Tjek på PubMedJournal of the American Medical Association, 19.03.2024
Tilføjet 19.03.2024
Experts detected a strain of SARS-CoV-2 with more than 30 changes in its spike protein compared with Omicron subvariant XBB.1.5, the US Centers for Disease Control and Prevention (CDC) announced. The newer Omicron subvariant, known as BA.2.87.1, has infected at least 9 people in South Africa since September 2023. No cases have been reported in the US or outside South Africa, the CDC noted in its update.
Læs mere Tjek på PubMedZheng Zhu, Shixiong Li, Junhao Fan, Shihao Shang, Yao Zhang, Qiong Zi, Jihao Zheng, Dongfang Wang, Xiaoli Mou, Kepu Liu, Maoxin Lv, Jianlin Yuan, Zhongfang Wang, Jingyou Yu
Journal of Medical Virology, 19.03.2024
Tilføjet 19.03.2024
Hsiao-Hui Tsou, Fang-Jing Lee, Shiow-Ing Wu, Byron Fan, Hsiao-Yu Wu, Yu-Hsuan Lin, Ya-Ting Hsu, Chieh Cheng, Yu-Chieh Cheng, Wei-Ming Jiang, Hung-Yi Chiou, Wei J. Chen, Chao A. Hsiung, Pau-Chung Chen, Huey-Kang Sytwu
PLoS One Infectious Diseases, 19.03.2024
Tilføjet 19.03.2024
by Hsiao-Hui Tsou, Fang-Jing Lee, Shiow-Ing Wu, Byron Fan, Hsiao-Yu Wu, Yu-Hsuan Lin, Ya-Ting Hsu, Chieh Cheng, Yu-Chieh Cheng, Wei-Ming Jiang, Hung-Yi Chiou, Wei J. Chen, Chao A. Hsiung, Pau-Chung Chen, Huey-Kang Sytwu Background Taiwan was a coronavirus disease 2019 (COVID-19) outlier, with an extraordinarily long transmission-free record: 253 days without locally transmitted infections while the rest of the world battled wave after wave of infection. The appearance of the alpha variant in May 2021, closely followed by the delta variant, disrupted this transmission-free streak. However, despite low vaccination coverage (
Læs mere Tjek på PubMedMaja Stosic, Dragana Plavsa, Verica Jovanovic, Marko Veljkovic, Dragan Babic, Aleksandra Knezevic, Vladan Saponjic, Dragana Dimitrijevic, Miljan Rancic, Marija Milic, Tatjana Adzic-Vukicevic
PLoS One Infectious Diseases, 19.03.2024
Tilføjet 19.03.2024
by Maja Stosic, Dragana Plavsa, Verica Jovanovic, Marko Veljkovic, Dragan Babic, Aleksandra Knezevic, Vladan Saponjic, Dragana Dimitrijevic, Miljan Rancic, Marija Milic, Tatjana Adzic-Vukicevic Severe acute respiratory infections (SARI) are estimated to be the cause of death in about 19% of all children younger than 5 years globally. The outbreak of coronaviral disease (COVID-19) caused by SARS-CoV-2, increased considerably the burden of SARI worldwide. We used data from a vaccine effectiveness study to identify the factors associated with SARS CoV-2 infection among hospitalized SARI patients. We recruited SARI patients at 3 hospitals in Serbia from 7 April 2022–1 May 2023. We collected demographic and clinical data from patients using a structured questionnaire, and all SARI patients were tested for SARS-CoV-2 by RT-PCR. We conducted an unmatched test negative case-control study. SARS-CoV-2 infected SARI patients were considered cases, while SARS CoV-2 negative SARI patients were controls. We conducted bivariate and multivariable logistic regression analysis in order to identify variables associated with SARS-CoV-2 infection. We included 110 SARI patients: 74 were cases and 36 controls. We identified 5 factors associated with SARS-CoV-2 positivity, age (OR = 1.04; 95% CI = 1.01–1.07), having received primary COVID-19 vaccine series (OR = 0.28; 95% CI = 0.09–0.88), current smoking (OR = 8.64; 95% CI = 2.43–30.72), previous SARS CoV-2 infection (OR = 3.48; 95% CI = 1.50–8.11) and number of days before seeking medical help (OR = 0.81; 95% CI = 0.64–1.02). In Serbia during a period of Omicron circulation, we found that older age, unvaccinated, hospitalized SARI patients, previously infected with SARS CoV-2 virus and those who smoked, were more likely to be SARS-CoV-2-positive; these patient populations should be prioritized for COVID vaccination.
Læs mere Tjek på PubMedKyung-Shin Lee, Min Jin Go, Youn Young Choi, Min-Kyung Kim, Jaehyun Seong, Ho Kyung Sung, Jaehyun Jeon, Hee-Chang Jang, Myoung-Hee Kim
PLoS One Infectious Diseases, 15.03.2024
Tilføjet 15.03.2024
by Kyung-Shin Lee, Min Jin Go, Youn Young Choi, Min-Kyung Kim, Jaehyun Seong, Ho Kyung Sung, Jaehyun Jeon, Hee-Chang Jang, Myoung-Hee Kim Background This study evaluated the clinical characteristics of patients with COVID-19 in Korea, and examined the relationship between severe COVID-19 cases and underlying health conditions during the Delta (September 20, 2021 to December 4, 2021) and the Omicron (February 20, 2022 to March 31, 2022) predominant period. Methods This study assessed the association between critical COVID-19 illness and various risk factors, including a variety of underlying health conditions, using multiple logistic regression models based on the K-COV-N cohort, a nationwide data of confirmed COVID-19 cases linked with COVID-19 vaccination status and the National Health Insurance claim information. Results We analyzed 137,532 and 8,294,249 cases of COVID-19 infection during the Delta and the Omicron variant dominant periods, respectively. During the Delta as well as the Omicron period, old age (≥80 years) showed the largest effect size among risk factors for critical COVID-19 illness (aOR = 18.08; 95% confidence interval [CI] = 14.71–22.23 for the Delta; aOR = 24.07; 95% CI = 19.03–30.44 for the Omicron period). We found that patients with solid organ transplant (SOT) recipients, unvaccinated, and interstitial lung disease had more than a two-fold increased risk of critical COVID-19 outcomes between the Delta and Omicron periods. However, risk factors such as urban residence, underweight, and underlying medical conditions, including chronic cardiac diseases, immunodeficiency, and mental disorders, had different effects on the development of critical COVID-19 illness between the Delta and Omicron periods. Conclusion We found that the severity of COVID-19 infection was much higher for the Delta variant than for the Omicron. Although the Delta and the Omicron variant shared many risk factors for critical illness, several risk factors were found to have different effects on the development of critical COVID-19 illness between those two variants. Close monitoring of a wide range of risk factors for critical illness is warranted as new variants continue to emerge during the pandemic.
Læs mere Tjek på PubMedBMC Infectious Diseases, 8.03.2024
Tilføjet 8.03.2024
Abstract Background The latent and incubation periods characterize the transmission of infectious viruses and are the basis for the development of outbreak prevention and control strategies. However, systematic studies on the latent period and associated factors with the incubation period for SAS-CoV-2 variants are still lacking. We inferred the two durations of Delta, BA.1, and BA.2 cases and analyzed the associated factors. Methods The Delta, BA.1, and BA.2 (and its lineages BA.2.2 and BA.2.76) cases with clear transmission chains and infectors from 10 local SAS-CoV-2 epidemics in China were enrolled. The latent and incubation periods were fitted by the Gamma distribution, and associated factors were analyzed using the accelerated failure time model. Results The mean latent period for 672 Delta, 208 BA.1, and 677 BA.2 cases was 4.40 (95%CI: 4.24 ~ 4.63), 2.50 (95%CI: 2.27 ~ 2.76), and 2.58 (95%CI: 2.48 ~ 2.69) days, respectively, with 85.65% (95%CI: 83.40 ~ 87.77%), 97.80% (95%CI: 96.35 ~ 98.89%), and 98.87% (95%CI: 98.40 ~ 99.27%) of them starting to shed viruses within 7 days after exposure. In 405 Delta, 75 BA.1, and 345 BA.2 symptomatic cases, the mean latent period was 0.76, 1.07, and 0.79 days shorter than the mean incubation period [5.04 (95%CI: 4.83 ~ 5.33), 3.42 (95%CI: 3.00 ~ 3.89), and 3.39 (95%CI: 3.24 ~ 3.55) days], respectively. No significant difference was observed in the two durations between BA.1 and BA.2 cases. After controlling for the sex, clinical severity, vaccination history, number of infectors, the length of exposure window and shedding window, the latent period [Delta: exp(β) = 0.81, 95%CI: 0.66 ~ 0.98, p = 0.034; Omicron: exp(β) = 0.82, 95%CI: 0.71 ~ 0.94, p = 0.004] and incubation period [Delta: exp(β) = 0.69, 95%CI: 0.55 ~ 0.86, p
Læs mere Tjek på PubMedBMC Infectious Diseases, 7.03.2024
Tilføjet 7.03.2024
Abstract Background The latent and incubation periods characterize the transmission of infectious viruses and are the basis for the development of outbreak prevention and control strategies. However, systematic studies on the latent period and associated factors with the incubation period for SAS-CoV-2 variants are still lacking. We inferred the two durations of Delta, BA.1, and BA.2 cases and analyzed the associated factors. Methods The Delta, BA.1, and BA.2 (and its lineages BA.2.2 and BA.2.76) cases with clear transmission chains and infectors from 10 local SAS-CoV-2 epidemics in China were enrolled. The latent and incubation periods were fitted by the Gamma distribution, and associated factors were analyzed using the accelerated failure time model. Results The mean latent period for 672 Delta, 208 BA.1, and 677 BA.2 cases was 4.40 (95%CI: 4.24 ~ 4.63), 2.50 (95%CI: 2.27 ~ 2.76), and 2.58 (95%CI: 2.48 ~ 2.69) days, respectively, with 85.65% (95%CI: 83.40 ~ 87.77%), 97.80% (95%CI: 96.35 ~ 98.89%), and 98.87% (95%CI: 98.40 ~ 99.27%) of them starting to shed viruses within 7 days after exposure. In 405 Delta, 75 BA.1, and 345 BA.2 symptomatic cases, the mean latent period was 0.76, 1.07, and 0.79 days shorter than the mean incubation period [5.04 (95%CI: 4.83 ~ 5.33), 3.42 (95%CI: 3.00 ~ 3.89), and 3.39 (95%CI: 3.24 ~ 3.55) days], respectively. No significant difference was observed in the two durations between BA.1 and BA.2 cases. After controlling for the sex, clinical severity, vaccination history, number of infectors, the length of exposure window and shedding window, the latent period [Delta: exp(β) = 0.81, 95%CI: 0.66 ~ 0.98, p = 0.034; Omicron: exp(β) = 0.82, 95%CI: 0.71 ~ 0.94, p = 0.004] and incubation period [Delta: exp(β) = 0.69, 95%CI: 0.55 ~ 0.86, p
Læs mere Tjek på PubMedChijioke Bennett, Wayne Woo, Mark Bloch, King Cheung, Paul Griffin, Rahul Mohan, Sachin Deshmukh, Mark Arya, Oscar Cumming, A Munro Neville, Toni G McCallum Pardey, Joyce S Plested, Shane Cloney-Clark, Mingzhu Zhu, Raj Kalkeri, Nita Patel, Alex Marcheschi, Jennifer Swan, Gale Smith, Iksung Cho, Gregory M Glenn, Robert Walker, Raburn M Mallory, Novavax 2019nCoV-311 Study Group
Lancet Infectious Diseases, 7.03.2024
Tilføjet 7.03.2024
All three coprimary endpoints were met in part 2 of the ongoing 2019nCoV-311 study. These data support the development of monovalent and/or bivalent vaccines for the most currently circulating variants, to optimise protection. With no new safety findings, further investigation of omicron-based subvariant vaccines is supported by the evidence.
Læs mere Tjek på PubMedMamadou Saliou Sow, Josue Togo, Lacy M. Simons, Souleymane Taran Diallo, Mohamed Lamine Magassouba, Mamadou Bhoye Keita, Anou Moise Somboro, Youssouf Coulibaly, Egon A. Ozer, Judd F. Hultquist, Robert Leo Murphy, Almoustapha Issiaka Maiga, Mamoudou Maiga, Ramon Lorenzo-Redondo
PLoS One Infectious Diseases, 7.03.2024
Tilføjet 7.03.2024
by Mamadou Saliou Sow, Josue Togo, Lacy M. Simons, Souleymane Taran Diallo, Mohamed Lamine Magassouba, Mamadou Bhoye Keita, Anou Moise Somboro, Youssouf Coulibaly, Egon A. Ozer, Judd F. Hultquist, Robert Leo Murphy, Almoustapha Issiaka Maiga, Mamoudou Maiga, Ramon Lorenzo-Redondo SARS-CoV-2 has claimed several million lives since its emergence in late 2019. The ongoing evolution of the virus has resulted in the periodic emergence of new viral variants with distinct fitness advantages, including enhanced transmission and immune escape. While several SARS-CoV-2 variants of concern trace their origins back to the African continent—including Beta, Eta, and Omicron–most countries in Africa remain under-sampled in global genomic surveillance efforts. In an effort to begin filling these knowledge gaps, we conducted retrospective viral genomic surveillance in Guinea from October 2020 to August 2021. We found that SARS-CoV-2 clades 20A, 20B, and 20C dominated throughout 2020 until the coincident emergence of the Alpha and Eta variants of concern in January 2021. The Alpha variant remained dominant throughout early 2021 until the arrival of the Delta variant in July. Surprisingly, despite the small sample size of our study, we also found the persistence of the early SARS-CoV-2 clade 19B as late as April 2021. Together, these data help fill in our understanding of the SARS-CoV-2 population dynamics in West Africa early in the COVID-19 pandemic.
Læs mere Tjek på PubMedJournal of Infectious Diseases, 6.03.2024
Tilføjet 6.03.2024
Abstract Detecting severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) reinfections is challenging with current serology assays and is further complicated by the marked decrease in routine viral testing practices as viral transmission increased during Omicron. Here, we provide proof-of-principle that high-avidity anti-nucleocapsid (N) antibodies detects reinfections after a single infection with higher specificity (85%; 95% confidence interval [95% CI], 80%–90%) compared to anti-N antibody levels (72%; 95% CI, 66%–79%) in a vaccinated cohort. This method could be used to retroactively investigate the epidemiology and incremental long-term health consequences of SARS-CoV-2 reinfections.
Læs mere Tjek på PubMedClinical Infectious Diseases, 6.03.2024
Tilføjet 6.03.2024
Abstract Background Immunocompromised patients (ICPs) have an increased risk for a severe and prolonged COVID-19. SARS-CoV-2 monoclonal antibodies (mAbs) were extensively used in these patients, but data from randomized trials that focus on ICPs are lacking. We evaluated the clinical and virological outcome of COVID-19 in ICPs treated with mAbs across SARS-CoV-2 variants.Methods In this multicenter prospective cohort study, we enrolled B-cell– and/or T-cell–deficient patients treated with casirivimab/imdevimab, sotrovimab, or tixagevimab/cilgavimab. SARS-CoV-2 RNA was quantified and sequenced weekly, and time to viral clearance, viral genome mutations, hospitalization, and death rates were registered.Results Two hundred and forty five patients infected with the Delta (50%) or Omicron BA.1, 2, or 5 (50%) variant were enrolled. Sixty-seven percent were vaccinated; 78 treated as outpatients, of whom 2 required hospital admission, but both survived. Of the 159 patients hospitalized at time of treatment, 43 (27%) required mechanical ventilation or died. The median time to viral clearance was 14 days (interquartile range, 7–22); however, it took >30 days in 15%. Resistance-associated spike mutations emerged in 9 patients in whom the median time to viral clearance was 63 days (95% confidence interval, 57–69; P < .001). Spike mutations were observed in 1 of 42 (2.4%) patients after treatment with 2 active mAbs, in 5 of 34 (14.7%) treated with actual monotherapy (sotrovimab), and 3 of 20 (12%) treated with functional monotherapy (ie, tixagevimab/cilgavimab against tixagevimab-resistant variant).Conclusions Despite treatment with mAbs, morbidity and mortality of COVID-19 in ICPs remained substantial. Combination antiviral therapy should be further explored and may be preferred in severely ICPs.
Læs mere Tjek på PubMedZoe Raglow, Diya Surie, James D Chappell, Yuwei Zhu, Emily T Martin, Jennie H Kwon, Anne E Frosch, Amira Mohamed, Julie Gilbert, Emily E Bendall, Auden Bahr, Natasha Halasa, H Keipp Talbot, Carlos G Grijalva, Adrienne Baughman, Kelsey N Womack, Cassandra Johnson, Sydney A Swan, Emilia Koumans, Meredith L McMorrow, Jennifer L Harcourt, Lydia J Atherton, Ashley Burroughs, Natalie J Thornburg, Wesley H Self, Adam S Lauring, Investigating Respiratory Viruses in the Acutely Ill (IVY) Network
The Lancet Microbe, 6.03.2024
Tilføjet 6.03.2024
In this cohort, prolonged replication-competent omicron SARS-CoV-2 infections were uncommon. Within-host evolutionary rates were similar across patients, but individuals with infections lasting longer than 56 days accumulated spike mutations, which were distinct from those seen globally. Populations at high risk should be targeted for repeated testing and treatment and monitored for the emergence of antiviral resistance.
Læs mere Tjek på PubMedNa Wu, Zhiwei Chen, Guanhua Zha, Zhiling Deng, Wenhan Huang, Dachuan Cai, Mingli Peng, Peng Hu, Lin Tang, Hong Ren
Journal of Medical Virology, 5.03.2024
Tilføjet 5.03.2024
Clinical Infectious Diseases, 2.03.2024
Tilføjet 2.03.2024
Abstract Background Hematopoietic cell transplant (HCT) or chimeric antigen receptor T cell (CAR-T) therapy recipients have high morbidity from severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection. There are limited data on outcomes from SARS-CoV-2 infection shortly before cellular therapy and uncertainty whether to delay therapy.Methods We conducted a retrospective cohort study of patients with SARS-CoV-2 infection within 90 days prior to HCT or CAR-T therapy between January 2020 and November 2022. We characterized the kinetics of SARS-CoV-2 detection, clinical outcomes following cellular therapy, and impact on delays in cellular therapy.Results We identified 37 patients (n=15 allogeneic HCT, n=11 autologous HCT, n=11 CAR-T therapy) with SARS-CoV-2 infections within 90 days of cellular therapy. Most infections (73%) occurred between March and November 2022, when Omicron strains were prevalent. Most patients had asymptomatic (27%) or mild (68%) coronavirus disease 2019 (COVID-19). SARS-CoV-2 positivity lasted a median of 20.0 days [IQR, 12.5-26.25]. The median time from first positive SARS-CoV-2 test to cellular therapy was 45 days [IQR, 37.75-70]; one patient tested positive on the day of infusion. After cellular therapy, no patients had recrudescent SARS-CoV-2 infection or COVID-19-related complications. Cellular therapy delays related to SARS-CoV-2 infection occurred in 70% of patients for a median of 37 days. Delays were more common after allogeneic (73%) and autologous (91%) HCT compared to CAR-T cell therapy (45%).Conclusions Patients with asymptomatic or mild COVID-19 may not require prolonged delays in cellular therapy in the context of contemporary circulating variants and availability of antiviral therapies.
Læs mere Tjek på PubMedNaru Zhang, Zihui Ye, Cun Li, Jie Zhou, Wei Xue, Luying Xiang, Yuewen Chen, Shuchang Chen, Rouhan Ye, Jingyin Dong, Jie Zhou, Shibo Jiang, Haijun Han
Journal of Medical Virology, 1.03.2024
Tilføjet 1.03.2024
Infectious Disease Modelling, 29.02.2024
Tilføjet 29.02.2024
Publication date: Available online 28 February 2024 Source: Infectious Disease Modelling Author(s): Hengcong Liu, Jun Cai, Jiaxin Zhou, Xiangyanyu Xu, Marco Ajelli, Hongjie Yu
Læs mere Tjek på PubMedMarek Petráš, Daniela Janovská, Danuše Lomozová, Martina Franklová, Pavel Dlouhý, Jozef Rosina, Ivana Králová Lesná
International Journal of Infectious Diseases, 26.02.2024
Tilføjet 26.02.2024
The SARS-CoV-2 pandemic necessitated the implementation of specific measures to minimize its impact on global public health. Non-pharmaceutical precautions played a crucial role in preventing the massive spread of SARS-CoV-2.[1] However, it was widely recognized that only widespread and global vaccination could effectively bring the virus under control.[2] The rapid development of various types of vaccines, supported by numerous countries and international organizations, was successfully completed within less than a year, enabling the commencement of widespread vaccination of the world\'s population in December 2020.
Læs mere Tjek på PubMedShishi Wu, Yanhong Li, Stefan Baral, Sharmistha Mishra, Maria Koh, Haley Golding, Jeffrey C. Kwong, Xiaolin Wei
PLoS One Infectious Diseases, 24.02.2024
Tilføjet 24.02.2024
by Shishi Wu, Yanhong Li, Stefan Baral, Sharmistha Mishra, Maria Koh, Haley Golding, Jeffrey C. Kwong, Xiaolin Wei Background Evidence on protection of different patterns of infection- and vaccine-acquired immunity against Omicron-associated severe illness is useful in planning booster vaccination strategies. We examined protection of prior SARS-CoV-2 infection, a third or a fourth COVID-19 vaccine dose, and hybrid immunity against Omicron-associated severe illness. Methods and findings This population-based cohort study followed five million individuals with at least one SARS-CoV-2 RT-PCR test before November 21, 2021 until an Omicron-associatedhospitalization or death. We used Cox regression models to estimate risks of Omicron-associated hospitalization and a composite severe outcome (hospitalized and death), among individuals with infection- and/or vaccination-acquired immunity. Individuals who were unvaccinated and had no history of a prior infection severed as the reference group. Both adjusted hazard ratios (HR) and corresponding protection (one minus adjusted HR), with 95% confidence intervals (CIs), were reported. Three doses provided 94% (95%CI 93–95) and 93% (95%CI 91–94) protection against Omicron-associated hospitalization at 2–3 and ≥3 months post-vaccination respectively, similar to the protection conferred by three doses and a prior infection (2–3 months: 99%, 95%CI 97–100; ≥3 months: 97%, 95%CI 92–99) and four doses (1 month: 87%, 95%CI 79–92; 1–2 months: 96%, 95%CI 92–98). In individuals ≥65 years old, protection of four doses increased to 95% (95%CI 91–98) at 1–2 months, significantly higher than that of three doses over the follow-up period. Similar results were observed with the composite severe outcome. Conclusion At least three antigenic exposures, achieved by vaccination or infection, confers significant protection against Omicron-associated hospitalization and death in all age groups. Our findings support a third dose for the overall population, regardless of prior infection status, and a fourth dose for the elderly to maintain high level of immunity and substantially reduce risk of severe illness at individual level.
Læs mere Tjek på PubMedJournal of Infectious Diseases, 23.02.2024
Tilføjet 23.02.2024
Abstract Background We assessed associations between binding antibody (bAb) concentration
Læs mere Tjek på PubMedBMC Infectious Diseases, 22.02.2024
Tilføjet 22.02.2024
Abstract Background In November 2021, the B.1.1.529 (omicron) variant of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) was detected in South Africa and subsequently rapidly spread around the world. Despite the reduced severity of the omicron variants, many patients become severely ill after infection and undergo invasive mechanical ventilation, but there are few reports on their background and prognosis throughout all variant periods. This study aimed to evaluate risk factors affecting patients requiring invasive mechanical ventilation with each variant of COVID-19 pandemic in Japan from nonvariants to omicron variants. Method This retrospective observational study was conducted at the Department of Emergency and Critical Care Medicine, Kansai Medical University Hospital and Kansai Medical University Medical Center, Osaka, Japan, from March 2020 to March 2023. Eligible patients were those who underwent invasive ventilation for COVID-19 pneumonia. We set the primary endpoint as in-hospital mortality. Multivariable logistic regression analysis adjusted for clinically important variables was performed to evaluate the clinical outcomes. Results We included 377 patients: 118 in the Nonvariant group, 154 in the Alpha group, 42 in the Delta group, and 63 patients in the Omicron group. Mortality rates for each group were 23.7% for the Nonvariant group, 12.3% for the Alpha group, 7.1% for the Delta group, and 30.5% for the Omicron group. Patient age was significantly associated with increased mortality (adjusted odds ratio [AOR]: 1.097; 95% confidence interval [CI]: 1.057–0.138, P
Læs mere Tjek på PubMedJiadi Gan, Huohuo Zhang, Jiaxuan Wu, Yi Liu, Pingping Liu, Ruixin Cheng, Xiumei Tang, Linhui Yang, Wenxin Luo, Weimin Li
Journal of Medical Virology, 22.02.2024
Tilføjet 22.02.2024
Clinical Infectious Diseases, 21.02.2024
Tilføjet 21.02.2024
To the Editor— From early in the coronavirus disease 2019 (COVID-19) pandemic, it became evident that the natural disease course undergoes different stages, from an initial mild viral phase to a more severe inflammatory phase and ultimately to a critical thromboinflammatory phase, often corresponding to acute respiratory distress syndrome in hospitalized patients. Most treatment guidelines have kept these disease stages in their algorithms, generally recommending early antiviral treatment for the mild to moderate disease, and immunomodulatory treatment for severe to critical disease [1]. However, as the virus has changed from pre-omicron to omicron variants, and the target population from immunologically naive to mostly vaccinated or recovered, these phases are less distinct [2].
Læs mere Tjek på PubMedSien Ombelet, Diego Castanares‐Zapatero, Fabian Desimpel, Frank Hulstaert, Sabine Stordeur, Dominique Roberfroid
Journal of Medical Virology, 21.02.2024
Tilføjet 21.02.2024
BMC Infectious Diseases, 21.02.2024
Tilføjet 21.02.2024
Abstract Background In November 2021, the B.1.1.529 (omicron) variant of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) was detected in South Africa and subsequently rapidly spread around the world. Despite the reduced severity of the omicron variants, many patients become severely ill after infection and undergo invasive mechanical ventilation, but there are few reports on their background and prognosis throughout all variant periods. This study aimed to evaluate risk factors affecting patients requiring invasive mechanical ventilation with each variant of COVID-19 pandemic in Japan from nonvariants to omicron variants. Method This retrospective observational study was conducted at the Department of Emergency and Critical Care Medicine, Kansai Medical University Hospital and Kansai Medical University Medical Center, Osaka, Japan, from March 2020 to March 2023. Eligible patients were those who underwent invasive ventilation for COVID-19 pneumonia. We set the primary endpoint as in-hospital mortality. Multivariable logistic regression analysis adjusted for clinically important variables was performed to evaluate the clinical outcomes. Results We included 377 patients: 118 in the Nonvariant group, 154 in the Alpha group, 42 in the Delta group, and 63 patients in the Omicron group. Mortality rates for each group were 23.7% for the Nonvariant group, 12.3% for the Alpha group, 7.1% for the Delta group, and 30.5% for the Omicron group. Patient age was significantly associated with increased mortality (adjusted odds ratio [AOR]: 1.097; 95% confidence interval [CI]: 1.057–0.138, P
Læs mere Tjek på PubMedBMC Infectious Diseases, 20.02.2024
Tilføjet 20.02.2024
Abstract The coronavirus disease of 2019 (COVID-19) resulted from an infection by severe acute respiratory syndrome coronavirus 2 (SARS‑CoV‑2) which is the main cause of acute respiratory distress syndrome (ARDS) in global population from 2019 on. It may contribute to higher rate of death among the patients with immunodeficiency based on recent reports. In addition, Good syndrome (GS) as a result of thymoma removal might cause in some long-lasting microbial infections. We described clinical aspects and viral mutations on a case of GS suffering from COVID-19. A 46-year-old man with fever, common respiratory disease symptoms and positive COVID-19 polymerase chain reaction (PCR) test, with the history of thymoma removal surgery was admitted to Masih Daneshvari Hospital, Tehran, Iran. Lung radiographs and oxygen saturation measurement disclosed considerable implication resulted in application of several anti-microbial medication. The delta variant (B.1.617.2 (21 J Clade)) was the strain isolated from the patient by sequencing methods done by the COVID-19 National Reference Laboratory (CNRL), Pasteur Institute of Iran, while the dominant strain circulated mostly among population was Omicron (B.1.1.529) at the time of sampling. Unfortunately, the patient had passed away a month later by sudden respiratory failure progressed in refractory septic shock. Despite the fact that opportunistic infections may lead the GS patients to a major health problematic condition, unusual persistent of infections such as non-dominant variant of SARS-Cov-2 could be observed through the disease timeline. Therefore, a fully screening of thymoma plus intra-host evolution monitoring of SARS-CoV-2 is highly recommended in immunocompromised patients.
Læs mere Tjek på PubMedBMC Infectious Diseases, 17.02.2024
Tilføjet 17.02.2024
Abstract Background Fear of a global public health issue and fresh infection wave in the persistent COVID-19 pandemic has been enflamed by the appearance of the novel variant Omicron BF.7 lineage. Recently, it has been seeing the novel Omicron subtype BF.7 lineage has sprawled exponentially in Hohhot. More than anything, risk stratification is significant to ascertain patients infected with COVID-19 who the most need in-hospital or in-home management. The study intends to understand the clinical severity and epidemiological characteristics of COVID-19 Omicron subvariant BF.7. lineage via gathering and analyzing the cases with Omicron subvariant in Hohhot, Inner Mongolia. Methods Based upon this, we linked variant Omicron BF.7 individual-level information including sex, age, symptom, underlying conditions and vaccination record. Further, we divided the cases into various groups and assessed the severity of patients according to the symptoms of patients with COVID-19. Clinical indicators and data might help to predict disadvantage outcomes and progression among Omicron BF.7 patients. Results In this study, in patients with severe symptoms, some indicators from real world data such as white blood cells, AST, ALT and CRE in patients with Omicron BF.7 in severe symptoms were significantly higher than mild and asymptomatic patients, while some indicators were significantly lower. Conclusions Above results suggested that the indicators were associated with ponderance of clinical symptoms. Our survey emphasized the value of timely investigations of clinical data obtained by systemic study to acquire detailed information.
Læs mere Tjek på PubMedBMC Infectious Diseases, 17.02.2024
Tilføjet 17.02.2024
Abstract Background Omicron has become the dominant variant of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) since first reported in November 2021. From the initially detected Wuhan lineage, sublineages BA.2, BA.4, BA.5, BQ, XAG, and XBB have emerged over time and are dominant in many countries. Therefore, the aim is to evaluate which variants are circulating and the clinical characteristics of inpatients infected with the Omicron variant. Methods This retrospective cohort study selected hospitalized patients admitted with respiratory symptoms to a hospital in the state of Rio Grande do Sul, Brazil, between June and July 2022. SARS-CoV-2 results were analyzed together with clinical outcomes and vaccination status. A viral genome library was prepared and forwarded to the Illumina MiSeq Platform for sequencing. Results In total, 37 genomes were sequenced. Concerning the Omicron sublineages, our study detected: BA.1 (21 K), BA.2 (21 L), BA.4 (22A), BA.5 (22B), BA.2.12.1 (22C), BQ.1 (22E), XBB (22F), and XAG recombinant. Omicron BA.5 (30%), BA.2 (19%), and BQ.1 (19%) were the most frequent sublineages, respectively. In total, 38% of patients present hypertension, and the most common symptoms were coughing (62%). Analyzing the COVID-19 vaccination, 30% of patients were fully vaccinated, 49% had a partial vaccination status, and 21% were unvaccinated (no dose). Conclusions BA.5 was the most prevalent sublineage in our study and surpassed the predominance of BA.2, as reported by the national genomic surveillance program. BQ.1 was diagnosed earlier in this study than it was officially reported in the state. Current data have demonstrated that the Omicron variant causes less severe infections, with the high rate of transmissibility and mutational landscape causing the rapid emergence of new sublineages.
Læs mere Tjek på PubMedInfection, 16.02.2024
Tilføjet 16.02.2024
Abstract Purpose Anti SARS-CoV-2 vaccination initially showed high effectiveness in preventing COVID-19. However, after the surge of variants of concern, the effectiveness dropped. Several studies investigated if this was related to the decrease of the humoral response over time; however, this issue is still unclear. The aim of this study was to understand whether SARS-CoV-2 anti-S IgG levels can be used to predict breakthrough infection risk and define the timing for further booster doses administration. Method Within the framework of the ORCHESTRA Project, over 20,000 health workers from 11 European centers were enrolled since December 2020. We performed two Cox proportional hazards survival analyses regarding pre-Omicron (from January to July 2021) and Omicron (December 2021–May 2022) periods. The serological response was classified as high (above the 75th percentile), medium (25th-75th), or low (
Læs mere Tjek på PubMedBMC Infectious Diseases, 16.02.2024
Tilføjet 16.02.2024
Abstract Background Fear of a global public health issue and fresh infection wave in the persistent COVID-19 pandemic has been enflamed by the appearance of the novel variant Omicron BF.7 lineage. Recently, it has been seeing the novel Omicron subtype BF.7 lineage has sprawled exponentially in Hohhot. More than anything, risk stratification is significant to ascertain patients infected with COVID-19 who the most need in-hospital or in-home management. The study intends to understand the clinical severity and epidemiological characteristics of COVID-19 Omicron subvariant BF.7. lineage via gathering and analyzing the cases with Omicron subvariant in Hohhot, Inner Mongolia. Methods Based upon this, we linked variant Omicron BF.7 individual-level information including sex, age, symptom, underlying conditions and vaccination record. Further, we divided the cases into various groups and assessed the severity of patients according to the symptoms of patients with COVID-19. Clinical indicators and data might help to predict disadvantage outcomes and progression among Omicron BF.7 patients. Results In this study, in patients with severe symptoms, some indicators from real world data such as white blood cells, AST, ALT and CRE in patients with Omicron BF.7 in severe symptoms were significantly higher than mild and asymptomatic patients, while some indicators were significantly lower. Conclusions Above results suggested that the indicators were associated with ponderance of clinical symptoms. Our survey emphasized the value of timely investigations of clinical data obtained by systemic study to acquire detailed information.
Læs mere Tjek på PubMedBMC Infectious Diseases, 14.02.2024
Tilføjet 14.02.2024
Abstract Background Omicron has become the dominant variant of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) since first reported in November 2021. From the initially detected Wuhan lineage, sublineages BA.2, BA.4, BA.5, BQ, XAG, and XBB have emerged over time and are dominant in many countries. Therefore, the aim is to evaluate which variants are circulating and the clinical characteristics of inpatients infected with the Omicron variant. Methods This retrospective cohort study selected hospitalized patients admitted with respiratory symptoms to a hospital in the state of Rio Grande do Sul, Brazil, between June and July 2022. SARS-CoV-2 results were analyzed together with clinical outcomes and vaccination status. A viral genome library was prepared and forwarded to the Illumina MiSeq Platform for sequencing. Results In total, 37 genomes were sequenced. Concerning the Omicron sublineages, our study detected: BA.1 (21 K), BA.2 (21 L), BA.4 (22A), BA.5 (22B), BA.2.12.1 (22C), BQ.1 (22E), XBB (22F), and XAG recombinant. Omicron BA.5 (30%), BA.2 (19%), and BQ.1 (19%) were the most frequent sublineages, respectively. In total, 38% of patients present hypertension, and the most common symptoms were coughing (62%). Analyzing the COVID-19 vaccination, 30% of patients were fully vaccinated, 49% had a partial vaccination status, and 21% were unvaccinated (no dose). Conclusions BA.5 was the most prevalent sublineage in our study and surpassed the predominance of BA.2, as reported by the national genomic surveillance program. BQ.1 was diagnosed earlier in this study than it was officially reported in the state. Current data have demonstrated that the Omicron variant causes less severe infections, with the high rate of transmissibility and mutational landscape causing the rapid emergence of new sublineages.
Læs mere Tjek på PubMedAlba EscaleraManon LaporteSam TurnerUmut KarakusAna S. Gonzalez-ReicheAdriana van de GuchteKeith FarrugiaZain KhalilHarm van BakelDerek SmithAdolfo García-SastreTeresa Aydilloa Department of Microbiology, Icahn School of Medicine at Mount Sinai, New York, NY, USAb Global Health and Emerging Pathogens Institute, Icahn School of Medicine at Mount Sinai, New York, NY, USAc Graduate School of Biomedical Sciences, Icahn School of Medicine at Mount Sinai, New York, NY, USAd Center for Pathogen Evolution, Department of Zoology, University of Cambridge, Cambridge, UKe Department of Genetics and Genomic Sciences, Icahn School of Medicine at Mount Sinai, New York, NY, USAf Icahn Genomics Institute, Icahn School of Medicine at Mount Sinai, New York, NY, USAg Department of Medicine, Division of Infectious Diseases, Icahn School of Medicine at Mount Sinai, New York, NY, USAh Department of Pathology, Molecular and Cell-Based Medicine, Icahn School of Medicine at Mount Sinai, New York, NY, USAi The Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York, NY, USA
Emerg Microbes Infect, 13.02.2024
Tilføjet 13.02.2024
Haoting Zhan, Yuchen Xie, Yongmei Liu, Linlin Cheng, Yi Xu, Xiaojing Qu, Chen Li, Xinru Guo, Haolong Li, Yuling Wang, Erhei Dai, Lijing Wang, Huixia Gao, Yongzhe Li
Journal of Medical Virology, 13.02.2024
Tilføjet 13.02.2024
Journal of Infectious Diseases, 13.02.2024
Tilføjet 13.02.2024
Abstract Background Monovalent Omicron XBB.1.5-containing vaccines were approved for Coronavirus disease 2019 (COVID-19) 2023-2024 immunizations.Methods This ongoing, open-label, phase 2/3 study evaluated mRNA-1273.815-monovalent (50-µg Omicron XBB.1.5-spike mRNA) and mRNA-1273.231-bivalent (25-µg each Omicron XBB.1.5- and BA.4/BA.5-spike mRNAs))vaccines, administered as 5th doses to adults who previously received a primary series, a 3rd dose of an original mRNA COVID-19 vaccine, and a 4th dose of an Omicron BA.4/BA.5 bivalent vaccine. Interim safety and immunogenicity results 29 days post-vaccination are reported.Results Participants (randomized 1:1) received 50-µg mRNA-1273.815(n=50) or mRNA-1273.231(n=51); median (interquartile range) months from the prior BA.4/BA.5-bivalent dose were 8.2 (8.1-8.3) and 8.3 (8.1-8.4), respectively. Neutralizing antibody (nAb) increased from pre-booster levels against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) variants tested. Day 29 nAb fold-increases from pre-booster levels were numerically higher against XBB.1.5, XBB.1.16, EG.5.1, BA.2.86, and JN.1 than BA.4/BA.5, BQ.1.1 and D614G. The monovalent vaccine also cross-neutralized FL.1.5.1, EG.5.1, BA.2.86, HK.3.1, HV.1 and JN.1 variants in a participant (n=20) subset, 15 days post-vaccination. Reactogenicity was similar to previously reported mRNA-1273 original and bivalent vaccines.Conclusions XBB.1.5-containing mRNA-1273 vaccines elicit robust, diverse nAb responses against more recent SARS-CoV-2 variants including JN.1, supporting the XBB.1.5-spike sequence selection for the 2023-2024 COVID-19 vaccine update.
Læs mere Tjek på PubMedQi Tang, Xubiao Xie, Longkai Peng, Linxin Yang, Yubin Chen, Shaojie Yu
International Journal of Infectious Diseases, 13.02.2024
Tilføjet 13.02.2024
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) pneumonia poses significant challenges to global health systems, particularly in severe and critical cases [1]. Coronavirus disease 2019 (COVID-19) patients are at risk of diffuse alveolar damage (DAD), acute respiratory distress syndrome (ARDS), and multi-organ failure, which are the main causes of death [2, 3]. Renal transplant recipients are particularly vulnerable to severe or critical COVID-19 illness, and mortality rates are high in this patient group [4-7].
Læs mere Tjek på PubMedJohn Van Dusen, Haley LeBlanc, Nicholas Nastasi, Jenny Panescu, Austin Shamblin, Jacob W. Smith, Michael G. Sovic, Amanda Williams, Mikkel B. M. Quam, Seth Faith, Karen C. Dannemiller
PLoS One Infectious Diseases, 10.02.2024
Tilføjet 10.02.2024
by John Van Dusen, Haley LeBlanc, Nicholas Nastasi, Jenny Panescu, Austin Shamblin, Jacob W. Smith, Michael G. Sovic, Amanda Williams, Mikkel B. M. Quam, Seth Faith, Karen C. Dannemiller Environmental surveillance of pathogens underlying infectious disease is critical to ensure public health. Recent efforts to track SARS-CoV-2 have utilized wastewater sampling to infer community trends in viral abundance and variant composition. Indoor dust has also been used for building-level inferences, though to date no sequencing data providing variant-scale resolution have been reported from dust samples, and strategies to monitor circulating variants in dust are needed to help inform public health decisions. In this study, we demonstrate that SARS-CoV-2 lineages can be detected and sequenced from indoor bulk dust samples. We collected 93 vacuum bags from April 2021 to March 2022 from buildings on The Ohio State University’s (OSU) Columbus campus, and the dust was used to develop and apply an amplicon-based whole-genome sequencing protocol to identify the variants present and estimate their relative abundances. Three variants of concern were detected in the dust: Alpha, Delta, and Omicron. Alpha was found in our earliest sample in April 2021 with an estimated frequency of 100%. Delta was the primary variant present from October of 2021 to January 2022, with an average estimated frequency of 91% (±1.3%). Omicron became the primary variant in January 2022 and was the dominant strain in circulation through March with an estimated frequency of 87% (±3.2%). The detection of these variants on OSU’s campus correlates with the circulation of these variants in the surrounding population (Delta p
Læs mere Tjek på PubMedSivaprakasam T. Selvavinayagam, Suvaiyarasan Suvaithenamudhan, Yean K. Yong, Kannan Hemashree, Manivannan Rajeshkumar, Anandhazhvar Kumaresan, Parthiban Arthydevi, Meganathan Kannan, Natarajan Gopalan, Ramachandran Vignesh, Amudhan Murugesan, Munusamy P. Sivasankaran, Sathish Sankar, Narayanaiah Cheedarla, Abdul R. Anshad, Sakthivel Govindaraj, Ying Zhang, Hong Y. Tan, Marie Larsson, Shanmugam Saravanan, Pachamuthu Balakrishnan, Langeswaran Kulanthaivel, Kamalendra Singh, Narcisse Joseph, Vijayakumar Velu, Siddappa N. Byrareddy, Esaki M. Shankar, Sivadoss Raju
Journal of Medical Virology, 9.02.2024
Tilføjet 9.02.2024
Infection, 9.02.2024
Tilføjet 9.02.2024
Abstract Purpose Anti SARS-CoV-2 vaccination initially showed high effectiveness in preventing COVID-19. However, after the surge of variants of concern, the effectiveness dropped. Several studies investigated if this was related to the decrease of the humoral response over time; however, this issue is still unclear. The aim of this study was to understand whether SARS-CoV-2 anti-S IgG levels can be used to predict breakthrough infection risk and define the timing for further booster doses administration. Method Within the framework of the ORCHESTRA Project, over 20,000 health workers from 11 European centers were enrolled since December 2020. We performed two Cox proportional hazards survival analyses regarding pre-Omicron (from January to July 2021) and Omicron (December 2021–May 2022) periods. The serological response was classified as high (above the 75th percentile), medium (25th-75th), or low (
Læs mere Tjek på PubMedJianpeng CaiHaocheng ZhangKun ZhuFeng ZhuYan WangSen WangFaren XieMeng ZhangLili RuiShuhong LiKe LinQuanlin XueGuanmin YuanHongyu WangYi ZhangZhangfan FuJieyu SongYanliang ZhangJingwen AiWenhong Zhanga Department of Infectious Diseases, Shanghai Key Laboratory of Infectious Diseases and Biosafety Emergency Response, National Medical Center for Infectious Diseases, Huashan Hospital, Shanghai Medical College, Fudan University, Shanghai, People’s Republic of Chinab Department of Respiratory and Critical Care Medicine, Affiliated Wuxi Fifth Hospital of Jiangnan University, Wuxi Fifth People's Hospital, Wuxi, People’s Republic of Chinac Department of Infectious Diseases, The Sixth People’s Hospital of Shenyang, Shenyang, People’s Republic of Chinad Department of Infectious Diseases, Nanjing Hospital of Chinese Medicine Affiliated to Nanjing University of Chinese Medicine, Nanjing, People’s Republic of Chinae Nanjing Research Center for Infectious Diseases of Integrated Traditional Chinese and Western Medicine, Nanjing, People’s Republic of Chinaf Shanghai Huashen Institute of Microbes and Infections, Shanghai, People’s Republic of China
Emerg Microbes Infect, 7.02.2024
Tilføjet 7.02.2024
Kyungmin Huh, Young-Eun Kim, Gi Hwan Bae, Jong Youn Moon, Ji-Man Kang, Jacob Lee, Jang-Whan Bae, Kyong Ran Peck, Jaehun Jung
Clinical Microbiology and Infection, 6.02.2024
Tilføjet 6.02.2024
To assess the association of primary and third doses of vaccination with the risk of post-acute sequelae of COVID-19.
Læs mere Tjek på PubMedPan Liu, Zixuan Xing, Xiaokang Peng, Mengyi Zhang, Chang Shu, Ce Wang, Ruina Li, Li Tang, Huijing Wei, Xiaoshan Ran, Sikai Qiu, Ning Gao, Yee Hui Yeo, Xiaoguai Liu, Fanpu Ji
Journal of Medical Virology, 3.02.2024
Tilføjet 3.02.2024
Stephan Gehring, Frank Kowalzik, Omar Okasha, Tobias Engelmann, Daniel Schreiner, Christian Jensen, Aline Mähringer-Kunz, Wendy Hartig-Merkel, Thao Mai Phuong Tran, Cornelia Oostvogels, Thomas Verstraeten
PLoS One Infectious Diseases, 31.01.2024
Tilføjet 31.01.2024
by Stephan Gehring, Frank Kowalzik, Omar Okasha, Tobias Engelmann, Daniel Schreiner, Christian Jensen, Aline Mähringer-Kunz, Wendy Hartig-Merkel, Thao Mai Phuong Tran, Cornelia Oostvogels, Thomas Verstraeten We assessed the seroepidemiology of SARS-CoV-2 infection and the incidence of coronavirus disease 2019 (COVID-19) before and during the rollout of COVID-19 vaccines, in a prospective observational cohort study on healthcare workers (HCWs) in a large tertiary hospital in Mainz, Germany. Antibody status was assessed during six visits between September 2020 and February 2022. Self-reported symptoms were collected using a smartphone application; symptomatic HCWs were tested using real-time polymerase chain reaction (RT-PCR) assays for SARS-CoV-2. Rates of virologically confirmed and severe COVID-19 were estimated using the U.S. Food and Drug Administration (FDA) and Coalition for Epidemic Preparedness Innovations (CEPI) case definitions, respectively, and were contrasted to background community transmission and circulating SARS-CoV-2 variants. A total of 3665 HCWs were enrolled (mean follow-up time: 18 months); 97 met the FDA definition of virologically confirmed COVID-19 (incidence rate (IR) 2.3/1000 person-months (PMs), one severe case). Most cases reported ≥2 symptoms, commonly, cough and anosmia or ageusia. Overall, 263 individuals seroconverted (IR 6.6/1000 PMs—2.9 times the estimated IR of COVID-19), indicating many cases were missed, either due to asymptomatic infections or to an atypical presentation of symptoms. A triphasic trend in anti-SARS-CoV-2 seroprevalence and seroconversion was observed, with an initial increase following the rollout of COVID-19 vaccines, a two-fold decline six months later, and finally a six-fold increase by the end of the study when Omicron was the dominant circulating variant. Despite the increase in infection rates at the end of the study due to the circulation of the Omicron variant, the infection and disease rates observed were lower than the published estimates in HCWs and rates in the general local population. Preferential vaccination of HCWs and the strict monitoring program for SARS-CoV-2 infection are the most likely reasons for the successful control of COVID-19 in this high-risk population.
Læs mere Tjek på PubMedBMC Infectious Diseases, 30.01.2024
Tilføjet 30.01.2024
Abstract Background The spread of SARS-CoV-2 has been studied at unprecedented levels worldwide. In jurisdictions where molecular analysis was performed on large scales, the emergence and competition of numerous SARS-CoV-2lineages have been observed in near real-time. Lineage identification, traditionally performed from clinical samples, can also be determined by sampling wastewater from sewersheds serving populations of interest. Variants of concern (VOCs) and SARS-CoV-2 lineages associated with increased transmissibility and/or severity are of particular interest. Method Here, we consider clinical and wastewater data sources to assess the emergence and spread of VOCs in Canada retrospectively. Results We show that, overall, wastewater-based VOC identification provides similar insights to the surveillance based on clinical samples. Based on clinical data, we observed synchrony in VOC introduction as well as similar emergence speeds across most Canadian provinces despite the large geographical size of the country and differences in provincial public health measures. Conclusion In particular, it took approximately four months for VOC Alpha and Delta to contribute to half of the incidence. In contrast, VOC Omicron achieved the same contribution in less than one month. This study provides significant benchmarks to enhance planning for future VOCs, and to some extent for future pandemics caused by other pathogens, by quantifying the rate of SARS-CoV-2 VOCs invasion in Canada.
Læs mere Tjek på PubMed